Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03600623 · ClinicalTrials.gov registry record · Early Phase 1
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
A Early Phase 1 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
NCT03600623 is a Early Phase 1 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants.
The verdict
NCT03600623, a Early Phase 1 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of high dose radiation called Stereotactic Body Radiation Therapy (SBRT). While the chemotherapy is standard of care, the strategy of adding SBRT has not been investigated. An increase in the percentage of patients who can proceed to have surgery to remove their disease is anticipated with this approach.
Interventions
- DRUG Folfirinox
- DRUG Gemcitabine nab-Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2020-07-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03600623
The ClinicalTrials.gov registry entry for NCT03600623 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Folfirinox is the first listed.
NCT03600623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03600623 about?
NCT03600623 is a clinical study titled "Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer". This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of high dose radiation called Stereotactic Body Radiation Therapy (SBRT). Wh...
What is the current status of trial NCT03600623?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2017-09-25. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03600623?
The interventions under investigation include: Folfirinox (DRUG), Gemcitabine nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03600623?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.